-
Oct 1, 2024 | 
mondaq.com | Christine M. Clements |Leonard Lipsky |Matthew J. Goldman |Michael Sutton
SM
Sheppard Mullin Richter & Hampton
More
Sheppard Mullin is a full service Global 100 firm with over 1,000 attorneys in 16 offices located in the United States, Europe and Asia. Since 1927, companies have turned to Sheppard Mullin to handle corporate and technology matters, high stakes litigation and complex financial transactions. In the US, the firm’s clients include more than half of the Fortune 100.
-
Jul 8, 2024 | 
mondaq.com | Christine M. Clements
Listen to this post
On Wednesday, a federal court in Texas stayed provisions of the
Centers for Medicare & Medicaid Services' ("CMS")
contract year 2025 Final Rule that amended the longstanding
Medicare Advantage ("MA") and Part D agent and broker
compensation methodology and prohibited certain terms in contracts
with third party marketing organizations ("TPMOs").
-
Apr 15, 2024 | 
natlawreview.com | Christine M. Clements
On April 4, 2024, the Centers for Medicare & Medicaid Services (“CMS”) issued the contract year 2025 (CY2025) Medicare Advantage and Part D final rule (the “Final Rule”). In addition to finalizing its CY2025 proposed rule, CMS also addressed several key provisions that remained from the CY2024 proposed rule.
-
Feb 12, 2024 | 
skiddle.com | Jon Pritchard |Christine M. Clements
St Benedict's Club events and ticketsSkiddle is an official primary ticket outlet for St Benedict's Club in Warrington. Find 1 upcoming events below. Tickets can be purchased directly from Skiddle: Do you promote an event at St Benedict's Club that's not listed? Use our free Event Promotion Centre to add/edit your events Hotels and AirBnbs near St Benedict's ClubNeed a place to stay?
-
Sep 28, 2023 | 
jdsupra.com | Christine M. Clements |John Tilton
The Centers for Medicare & Medicaid Services (“CMS”) released the final rule on risk adjustment data validation (“RADV”) audits of Medicare Advantage (“MA”) organizations (the “Final Rule”) on January 30, 2023. Among other changes, this Final Rule will allow CMS to audit a sample of an MA organization’s (“MAO”) diagnoses reported for risk adjustment purposes (from 2018 and later) and then use the audit findings to calculate an extrapolated improper payment amount for the MAO’s contract.
-
Sep 6, 2023 | 
lexblog.com | Christine M. Clements |Carmen Jule
The status of the independent dispute resolution (IDR) process under the No Surprises Act (NSA) is ever-evolving. Providers are waiting on the sidelines as cases weave their way through the court system. While the IDR process is currently on hold, it is incumbent on providers, payors, and individuals to remain vigilant and stay abreast of the forthcoming changes. Where do things stand now and what can we expect in the future?
-
Mar 16, 2023 | 
jdsupra.com | Christine M. Clements |Sheela Ranganathan
The Inflation Reduction Act (the “IRA”) requires drug manufacturers to pay rebates to Medicare when the prices of their Part B and Part D prescription drug increase faster than the rate of inflation. We recently discussed the guidance documents issued by the Centers for Medicare and Medicaid Services (“CMS”) detailing the proposed implementation of the Medicare Part B and Medicare Part D Prescription Drug Inflation Rebate Programs.
-
Mar 15, 2023 | 
natlawreview.com | Christine M. Clements
Wednesday, March 15, 2023 The Inflation Reduction Act (the “IRA”) requires drug manufacturers to pay rebates to Medicare when the prices of their Part B and Part D prescription drug increase faster than the rate of inflation. We recently discussed the guidance documents issued by the Centers for Medicare and Medicaid Services (“CMS”) detailing the proposed implementation of the Medicare Part B and Medicare Part D Prescription Drug Inflation Rebate Programs.
-
Mar 15, 2023 | 
lexblog.com | Christine M. Clements |Sheela Ranganathan
The Inflation Reduction Act (the “IRA”) requires drug manufacturers to pay rebates to Medicare when the prices of their Part B and Part D prescription drug increase faster than the rate of inflation. We recently discussed the guidance documents issued by the Centers for Medicare and Medicaid Services (“CMS”) detailing the proposed implementation of the Medicare Part B and Medicare Part D Prescription Drug Inflation Rebate Programs.
-
Mar 15, 2023 | 
lexology.com | Christine M. Clements |Sheela Ranganathan
The Inflation Reduction Act (the “IRA”) requires drug manufacturers to pay rebates to Medicare when the prices of their Part B and Part D prescription drug increase faster than the rate of inflation. We recently discussed the guidance documents issued by the Centers for Medicare and Medicaid Services (“CMS”) detailing the proposed implementation of the Medicare Part B and Medicare Part D Prescription Drug Inflation Rebate Programs.
